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The aim of this study was to evaluate the histologic diagnosis of hypovascular hepatic lesions showing 
hypointensity on hepatobiliary phase images of gadolinium-ethoxybenzyl-diethylenetriamine pentaa-
cetic acid (Gd-EOB-DTPA)-enhanced MRI (EOB-MRI).  In 38 patients with hepatocellular carcinoma 
(HCC) after curative treatments and 18 patients with liver cirrhosis,  105 hypovascular nodules that 
were hypointense at the hepatobiliary phase of EOB-MRI were biopsied and the clinical usefulness of 
these EOB-MRI ﬁndings for the diagnosis of HCC was examined.  Of the 105 nodules (median diameter
＝12mm),  78 (74.3ｵ),  11 (10.5ｵ),  and 16 (15.2ｵ) were diagnosed as HCC,  dysplastic,  and non-neoplas-
tic,  respectively.  The positive predictive value (PPV) of hypointensity at the hepatobiliary phase of 
EOB-MRI for the diagnosis of HCC increased to 77-90ｵ when combined with the following factors:  
washout appearance on the delayed phase of triple-phase CT,  hyperintensity in diﬀusion-weighted 
image of MRI,  or the appearance of a hypoechoic part in ultrasonography.  PPV increased to 100ｵ 
when all 3 factors were positive.  A relatively large proportion of hypovascular lesions that showed 
hypo-intensity in the hepatobiliary phase were conﬁrmed to be HCC,  and the accuracy of HCC 
increased when combined with other imaging ﬁndings.
Key words: hepatocellular carcinoma,  hypovascular,  diagnosis,  gadolinium-ethoxybenzyl-diethylenetriamine 
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epatocellular carcinoma (HCC) is the most fre-
quent primary hepatic malignancy and is cur-
rently recognized as a major cause of death in cir-
rhotic patients.  Epidemiological data have indicated 
that the incidence of HCC is increasing,  and that 
HCC will be a worldwide health problem in the near 
future [1-3].
　 Progress in the imaging modalities for diagnosing 
HCC is remarkable.  The development of the multi-
detector row CT,  CT during hepatic arteriography 
(CTHA),  or CT during arterial portography (CTAP) 
has made it possible to detect small hepatic nodules 
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[4,  5].  Enhancement at the arterial phase and 
hypoattenuation at the portal phase detected by these 
contrast-enhanced imaging techniques is now regarded 
as a distinctive feature of HCC in cirrhosis.  However,  
the deﬁnitive diagnosis of a hypovascular nodular 
lesion remains a critical challenge for clinicians [6].  
The issue is particularly complicated for small nod-
ules,  because many of these may be preneoplastic 
lesions [7],  such as low-grade dysplastic nodules or 
high-grade dysplastic nodules [8].  At present,  a 
biopsy is necessary for the deﬁnitive diagnosis of these 
hypovascular nodules.
　 Gadolinium-ethoxybenzyl-diethylenetriamine pen-
taacetic acid (Gd-EOB-DTPA) (Primovist,  Bayer 
Schering Pharma AG,  Berlin,  Germany) is a new 
liver-speciﬁc contrast agent for magnetic resonance 
imaging (MRI) [9-11].  This contrast agent has unique 
characteristics.  It is taken up into normally function-
ing hepatocytes and is excreted in the bile ducts in 
10-20 minutes after injection.  Consequently,  lesions 
deﬁcient in normally functioning hepatocytes can be 
visualized as hypointense regions in this hepatobiliary 
phase [9].  However,  few studies have been conducted 
to determine whether these minutely imaged lesions in 
patients with cirrhosis are indeed HCC [11-15].
　 Therefore,  we conducted a retrospective study to 
clarify the histologic diagnosis of hypovascular hepatic 
lesions showing hypointensity on hepatobiliary phase 
images of Gd-EOB-DTPA enhanced MRI.
Patients and Methods
　 Patients. Between April 2008 and May 2009,  
33 patients with liver cirrhosis and 44 patients with 
HCC after curative treatment (11 surgical resection,  
30 radiofrequency ablation,  1 microwave coagulation 
and 2 percutaneous ethanol injection) were examined 
with both Gd-EOB-DTPA-enhanced MRI (EOB-MRI) 
and ultrasonography (US) for the surveillance of HCC.  
A total of 138 hypointense liver lesions at the hepato-
biliary phase of EOB-MRI were detected.  Among 
them,  29 nodules that showed enhancement at the 
hepatic arterial phase in triple-phase CT or MR imag-
ing were excluded.  All of the remaining 109 hypovas-
cular nodules were histologically diagnosed by biop-
sies.  Three nodules were excluded because tissue 
specimens were too small to be diagnosed accurately,  
and one nodule of cholangiocellular carcinoma was also 
excluded.  Thus,  105 nodules in 56 patients (18 patients 
with liver cirrhosis and 38 patients with HCC after 
curative treatment) were included in this study.
　 Methods. The patients with cirrhosis under-
went US every 3 months and CT or MRI every year 
for the surveillance of HCC.  The patients with HCC 
after curative treatment underwent US every 2 or 3 
months and CT or MRI at least once a year.
　 MR imaging was performed on a 1.5-T MR system 
(Magnetom Avanto,  Siemens,  Erlangen,  Germany) 
with a three-dimensional (3D) volumetric interpolated 
breathhold examination (VIBE).  The technical param-
eters were: repetition time (TR,  msec)/echo time 
(TE,  msec),  4.04 msec/minimum; ﬂip angle (FA),  15 
degrees; ﬁeld of view (FOV),  320mm; thickness,  
3.5mm; partition,  52; matrix,  256×154; generalized 
autocalibrating partially parallel acquisition (GRAPPA) 
with an acceleration factor of 2 and a bandwidth of 
340 Hz per pixel.  All patients received a dose of 
0.025mmol/kg Gd-EOB-DTPA intravenously at a rate 
of 2mL/s.
　 After the administration of the contrast material,  
triple-phase images (arterial phase,  35 sec after arte-
rial phase,  70 sec after arterial phase) were obtained.  
The arterial phase was determined by the automatic 
triggering techniques that are commercially available 
as bolus detection software termed C.A.R.E (Combined 
Application Reduce Exposure) by Siemens.  Dynamic 
imaging and hepatobiliary phase imaging (20 min after 
the administration of contrast material) were per-
formed using the T1-weighted 3D-VIBE sequence with 
fat suppression.  Single-shot echo-planner (EPI) diﬀu-
sion-weighted images (DWIw) were acquired as 
follows: TR/TE,  1,300/85msec; FOV,  320×240mm;  
slice thickness,  7.0mm; matrix,  128×90; EPI fac-
tor,  62; parallel imaging (GRAPPA with accelera-
tion factor of 2); 3 separate b-values (0,  50,  1,000 s/
mm2; and acquisition,  prospective acquisition correc-
tion [PACE]).
　 All patients were examined by a 64-MDCT system 
(Aquilion 64,  Toshiba Medical Systems,  Tokyo,  Japan).  
Precontrast and triple-phase (arterial,  portal venous,  
and equilibrium phases) post-contrast scans of the liver 
were acquired.  An automatic bolus-tracking program 
(Real Prep,  Toshiba Medical Systems) was used to set 
the scanning timing for arterial phase after contrast 
injection.  Arterial-phase scanning was started 16 sec 
after triggering.  Portal venous and equilibrium-phase 
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scanning were started 60 and 240 sec after injection.  
Iohexol (Omnipaque,  Daiichi-Sankyo,  Tokyo,  Japan) 
with an iodine concentration of 300mgI/mL was 
administered,  and we delivered 600mgI/kg in 25 sec.  
The regions that showed hypoattenuation at the portal 
venous phase of triple-phase CT were deﬁned as hav-
ing a washout appearance.
　 Ultrasonographic examinations were performed 
using SSA-770A (Toshiba Medical Systems,  Tokyo,  
Japan) or Prosound α10 (Aloka,  Tokyo,  Japan) by 2 
board-certiﬁed hepatologists who are also board-certi-
ﬁed fellows of the Japan Society of Ultrasonics in 
Medicine.
　 Each tumor-aimed biopsy was performed percuta-
neously under US guidance using a 21-gauge needle at 
least twice and put into a bottle ﬁlled with formalin to 
avoid sampling errors.  All specimens were stained 
with hematoxylin-eosin and silver impregnation.  
Histological diagnosis was performed by 2 board-cer-
tiﬁed pathologists and 2 board-certiﬁed hepatologists 
according to the criteria outlined by an International 
Working Party.
　 All images were reviewed independently by 2 
board-certiﬁed hepatologists,  and compared with the 
histological ﬁndings.  Disagreements about the inter-
pretations were resolved by consensus.
　 The continuous data (e.g.,  age,  tumor size and 
values of tumor markers) were analyzed using 
Wilcoxon rank-sum test.  Chi-squared tests or Fisherʼs 
exact test was used for categorical parameters.  All 
statistical analyses were performed using JMP soft-
ware,  version 8.0.1 (SAS Institute,  Inc.,  Cary,  NC,  
USA).  P-values smaller than 0.05 were considered 
signiﬁcant.
　 Informed consent was obtained from all patients.  
The study protocol conformed to the ethical guidelines 
of the World Medical Association Declaration of 
Helsinki,  and was approved by the ethical committee 
of the institute.
Results
　 Patient data were obtained and compared between 
groups with and without previous treatments of HCC 
(Table 1).  The median age of the 56 patients was 70 
years (range 53-83 years).  The age,  gender,  cause of 
liver disease,  tumor markers,  and the median size of 
nodules did not diﬀer signiﬁcantly between the 2 
groups.  The positive ratio of HCC did not diﬀer 
between patients with and without previous treatment 
for HCC (70.1ｵ v.s. 81.6ｵ,  p＝0.20).
　 Of the 105 nodules,  78 nodules (74.3ｵ) were his-
tologically diagnosed as HCC (77 nodules,  well dif-
ferentiated HCC; 1 nodule,  moderately diﬀerentiated 
HCC).  Eleven (10.5ｵ) and 16 nodules (15.2ｵ) were 
diagnosed as dysplastic and non-neoplastic lesions,  
respectively.
　 Table 2 shows the imaging patterns of pathologi-
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Table 1　 Patient data and characteristics of nodules
total
Previous treatment for HCC
P value
yes no
Patient characteristics
　Number (%) 56 38 (67.9) 18 (32.1)
　Age (yr) 70 (53-83) 69 (53-83) 71 (57-83) 0.35
　Gender (male/female) 41/15 29/9 12/6 0.52
　Cause (HCV/HBV/HCV and HBV/other) 49/5/1/1 33/4/0/1 16/1/1/0 0.40
　AFP (ng/mL) 12.0 (2.0-383.4) 11.2 (2.0-91.1) 20.2 (2.5-383.4) 0.40
　AFP-L3 (%) 0.5 (0.0-27.0) 0.0 (0.0-27.0) 0.5 (0.0-0.5) 0.21
　DCP (mAU/mL) 24 (10-166) 22 (10-81) 26 (13-166) 0.30
Nodule characteristics
　Number (%) 105 67 (63.8) 38 (36.2)
　Size (mm) 12 (6-20) 12 (6-20) 12 (6-19) 0.47
　HCC (%) 78 (74.3) 47 (70.1) 31 (81.6) 0.20
All variables are indicated as median (range) unless otherwise noted.
HCC,  hepatocellular carcinoma; HCV,  hepatitis C virus; HBV,  hepatitis B virus; AFP,  alpha-fetoprotein; AFP-L3,  lectin-bound alpha-
fetoprotein; DCP,  des-gamma-carboxy prothrombin.
cally diagnosed nodules.  Of the 78 HCCs,  62 nodules 
(79ｵ) contained hypoechoic regions on conventional 
US B-mode,  and 71 (91ｵ) showed a washout appear-
ance at the portal venous phase of triple-phase CT.  In 
the meantime,  33 (42ｵ),  28 (36ｵ) and 26 (33ｵ) 
nodules showed hyperintensity on T1,  T2 and diﬀu-
sion-weighted images,  respectively.
　 As shown in Table 3,  the positive predictive value 
(PPV) of hypointensity at the hepatobiliary phase of 
EOB-MRI (EOB-hypo) for the diagnosis of HCC was 
74.3ｵ (95ｵ C.I.,  65.2-81.7).  It increased to 77.2ｵ 
when the nodule showed a washout appearance on the 
delayed phase of triple-phase CT,  81.6ｵ when the 
nodule contained hypoechoic regions in conventional 
US B-mode,  and 83.9ｵ when the nodule showed 
hyperintensity in DWI.  In addition,  PPV was increased 
to 85.9-91.3ｵ when combined with 2 of these 3 fac-
tors.  All of the 21 nodules that were positive for 
these 3 factors were diagnosed as HCC (Fig.  1).
Discussion
　 Gd-EOB-DTPA is a new type of contrast enhance-
ment material for MRI,  and the enhancement eﬀect at 
the hepatobiliary phase is independent from the blood 
ﬂow.  Gd-EOB-DTPA is transported into hepatocytes 
via organic anion transporters (OATPs) and excreted 
into bile canaliculi via the multidrug resistance-associ-
ated protein MRP2.  OATP1B3,  which is expressed 
in the basolateral membrane of hepatocytes,  is espe-
cially important for transport of Gd-EOB-DTPA [9,  
16,  17].  Typically,  accumulation of Gd-EOB-DTPA 
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Table 2　 Imaging patterns and pathological characterization of nodules
Number (%)
US appearance on
B-mode
Signal intensity at
delayed phase of
dynamic study
Signal intensity of MRI
T1 W.I. T2 W.I. diﬀusion W.I.
hyper-echoic/
hyper- and hypo-echoic
/hypo-echoic
iso/hypo hyper/ iso/hypo hyper/ iso/hypo
hyper/ iso/
no study
Hepatocellular carcinoma 78 (74.3) 16/20/42 7/71 33/34/11 28/40/10 26/50/2
　Well diﬀerentiated 77 (73.3) 15/20/42 7/70 33/33/11 28/39/10 26/49/2
　Mod. diﬀerentiated 1 (1.0) 1/0/0 0/1 0/1/0 0/1/0 0/1/0
Dysplastic nodules 11 (10.5) 4/3/4 1/10 6/4/1 5/4/2 3/8/0
　Low-grade 8 (7.6) 2/3/3 1/7 4/3/1 2/4/2 2/6/0
　High-grade 3 (2.9) 2/0/1 0/3 2/1/0 3/0/0 1/2/0
No malignancy 16 (15.2) 8/4/4 5/11 3/7/6 5/7/4 2/13/1
Table 3　 Positive predictive value for the diagnosis of hypovascular HCC
Number of nodules HCC PPV (95% C.I.)
Hypointense at the hepato-biliary phase of EOB-MRI 105 78 74.3 (65.2-81.7)
　Combine with one factor
　Wash out at delayed phase (W/O)  92 71 77.2 (67.6-84.6)
　Contains hypoechoic lesion on US (US)  76 62 81.6 (71.4-88.7)
　Hyperintensity at diﬀusion weighted image (Diﬀ)  31 26 83.9 (67.4-92.9)
　Combine with two factors
　W/O＋US  64 55 85.9 (75.4-92.4)
　W/O＋Diﬀ  29 26 89.7 (73.6-96.4)
　US＋Diﬀ  23 21 91.3 (73.2-97.6)
　Combine with three factors
　W/O＋US＋Diﬀ  21 21 100 (74.5-100)
HCC,  hepatocellular carcinoma; PPV,  positive predictive value; EOB-MRI,  Gd-EOB-DTPA-enhanced magnetic resonance imaging.
is inhibited in malignant liver lesions,  such that they 
appear hypointense at the hepatobiliary phase [9].
　 Because so-called “early HCCs” do not show a clas-
sical HCC pattern,  which is enhancement at an early 
arterial phase and washout at a portal venous phase,  
it is very diﬃcult to distinguish them from other non-
malignant liver nodules by traditional imaging modali-
ties.  In the present study,  we found that 74.3ｵ of 
hypovascular nodules that showed hypointensity at the 
hepatobiliary phase of EOB-MRI were HCCs.  This 
PPV for the diagnosis of small hypovascular HCC is 
relatively high compared with other imaging modali-
ties.  Tajima et al.  reported that only 9 of 19 (47ｵ) 
liver nodules showing hypoattenuation on CTHA were 
diagnosed as well-diﬀerentiated HCC [18].  Also,  
Hayashi et al.  reported that 1 of 9 (11ｵ) liver nodules 
showing isoattenuation or hypoattenuation on CTHA 
and hypoattenuation on CTAP were diagnosed as well 
diﬀerentiated HCC [5].
　 Recently,  other liver-speciﬁc contrast agents have 
been used,  and those agents can also reveal hypovas-
cular HCCs in some cases.  Superparamagnetic iron 
oxide (SPIO) is a tissue-speciﬁc MR imaging contrast 
that is taken up by Kupﬀer cells in the liver;  
however,  most of the well-diﬀerentiated HCCs had a 
similar number of Kupﬀer cells in the tumorous and 
nontumorous tissues.  Therefore,  it is diﬃcult to dis-
tinguish dysplastic nodules from well-diﬀerentiated 
HCCs by SPIO-enhanced MR imaging alone [19].  
Sonazoid is a lipid-stabilized suspension of perﬂuo-
robutane and is also taken up by the Kupﬀer cells.  
According to a recent report,  only 3 of 13 (23.1ｵ) 
well-diﬀerentiated HCCs showed a perfusion defect in 
the Kupﬀer phase so that the diagnosis of hypovascu-
lar HCC by this method is also limited [20].
　 In our study,  PPV of EOB-MRI at the hepatobil-
iary phase was high (74.3ｵ); however,  the result is 
somewhat unsatisfactory because the false positive rate 
was 26ｵ.  To achieve a higher PPV,  we combined it 
with 3 independent factors: washout appearance at the 
delayed phase on triple-phase CT,  the existence of a 
hypoechoic region in conventional US B-mode,  and 
hyperintensity in DWI.  As shown in Table 3,  the 
PPV was raised to about 80ｵ when combined with 
one factor,  and increased to almost 90ｵ when com-
bined with 2 factors.  When all 3 factors were posi-
tive,  PPV reached 100ｵ.  Liver biopsy for the 
diagnosis of HCC has several potential risks,  such as 
intra-abdominal bleeding and the dissemination of 
tumor cells.  The combination of examinations that we 
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Fig. 1　 Typical ﬁndings of hypovascular hepatocellular carcinoma (HCC).  A,  T1-weighted enhanced MRI (arterial phase); B,  
Abdominal MRI (diﬀusion weighted image,  b＝1,000); C,  Gd-EOB-DTPA-enhanced MRI (hepatobiliary phase); D,  Abdominal 
ultrasonography; E,  Histological ﬁnding of biopsied specimen (well-diﬀeretinated HCC).
presented in this study would be very helpful in cases 
in which hypovascular nodules are found in cirrhotic 
livers and physicians must decide whether to biopsy 
them or not.
　 The limitations of our study are as follows.  First,  
there must be some sampling errors in US guided 
biopsies.  Second,  the pathologists and hepatologists 
were diﬀerent in each case,  although they were all 
board-certiﬁed doctors.
　 In conclusion,  a relatively large proportion of 
hypovascular hepatic lesions that were hypo-intense in 
hepatobiliary phase images of Gd-EOB-DTPA-
enhanced MRI were conﬁrmed to be HCC,  and the 
accuracy of the diagnosis of HCC increased when 
combined with other imaging ﬁndings.
　 Further large-scale studies are needed to verify 
more precisely the value of Gd-EOB-DTPA-enhanced 
MRI for the diagnosis of HCC and to integrate it into 
a diagnostic algorithm.
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